Drug Discovery and Development Solutions for Liver Cancer

Our In Vitro Efficacy Testing Service accelerates liver cancer drug discovery by providing robust, sensitive platforms for evaluating compound efficacy, cytotoxicity, and mechanism of action. We specialize in hepatocellular carcinoma, targeting key pathways such as PI3K/AKT, Wnt/β-catenin, and proteins including B-Raf, Bcl2, RET, Src, and TNF. Utilizing advanced ATP, chemiluminescent, ELISA, fluorescent, and RNA-based assays, we deliver comprehensive assessments of cell viability, protein expression, and gene modulation. Key pharmacological parameters—IC-50, MEC, and MIC—guide lead optimization, supporting informed decision-making and accelerating preclinical development for innovative liver cancer therapeutics.

Alfa Cytology offers comprehensive in vivo animal model development for liver cancer, supporting preclinical research and drug discovery. Utilizing 280 models across five species and 45 strains, we provide xenograft, allograft, genetically engineered, chemically-induced, dietary, PDX, and organoid models. Our capabilities include custom model generation, tumor implantation, advanced imaging, and robust analytical techniques such as histopathology, immunohistochemistry, flow cytometry, and molecular biology. With rigorous quality control, expert project management, and end-to-end support, we deliver reliable, translatable results to accelerate your liver cancer research and therapeutic development. Partner with us for tailored, data-driven solutions.

Our PK/PD research service for liver cancer delivers comprehensive support for drug development, utilizing advanced analytical methods such as HPLC, LC-MS, and ELISA to accurately quantify drugs, metabolites, and biomarkers. We offer diverse administration routes and extensive compartment analysis across multiple animal models, enabling robust evaluation of absorption, distribution, metabolism, and excretion. Our studies inform dosing strategies, optimize therapeutic efficacy, and assess safety profiles. With expertise in translational research, we provide critical insights into concentration-effect relationships and interspecies scaling, accelerating the progression of targeted therapies from preclinical discovery to clinical application for liver cancer treatment.

Alfa Cytology provides comprehensive in vivo toxicity assessment services tailored for liver cancer drug development. Utilizing advanced analytical platforms, diverse animal models, and validated methodologies, we conduct acute, chronic, organ-specific, systemic, and genotoxicity studies. Our GLP-compliant protocols, high-throughput histopathology, and automated clinical chemistry ensure data integrity and regulatory alignment. Specialized endpoints such as liver enzyme profiling and hepatic imaging offer nuanced insights into safety and mechanism of toxicity. By integrating rigorous quality controls and robust biostatistics, Alfa Cytology empowers sponsors with critical, reliable data to accelerate and de-risk liver cancer therapeutic development.

Alfa Cytology offers research-focused biomarker analysis services for Liver Cancer, utilizing integrated multi-omics approaches—including genomics, transcriptomics, proteomics, and metabolomics—to explore molecular signatures and networks. We employ high-throughput screening and advanced analytical platforms such as immunoassays, mass spectrometry, and molecular diagnostics to investigate and evaluate candidates with potential as Liver Cancer biomarkers. Our methodologies emphasize the systematic assessment of biomarker expression, mutation status, and pathway involvement, supporting rigorous candidate evaluation. Through technical expertise and objective research protocols, we facilitate the exploration of biomarker relevance in preclinical Liver Cancer studies without making definitive validation claims.